MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- WOCKHARDT LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Wockhardt Quarterly Results 
(WOCK)
Here are the latest quarterly results of Wockhardt. For more details, see the Wockhardt financial fact sheet and Wockhardt share price and chart. For a sector overview, read our pharmaceuticals sector report.
Wockhardt Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 8,911 | 10,223 | 10,053 | 10,183 | 10,077 | 11,257 | 10,459 | 9,791 | |
| Other income | Rs m | 370 | 546 | 371 | -84 | 74 | 61 | 21 | 54 | |
| Turnover | Rs m | 9,281 | 10,768 | 10,424 | 10,099 | 10,151 | 11,318 | 10,479 | 9,846 | |
| Expenses | Rs m | 9,511 | 10,010 | 9,586 | 10,244 | 10,033 | 10,583 | 10,637 | 9,236 | |
| Gross profit | Rs m | -4,183 | 213 | 467 | -45 | 133 | 755 | -178 | 556 | |
| Depreciation | Rs m | 372 | 362 | 380 | 382 | 392 | 402 | 412 | 454 | |
| Interest | Rs m | 611 | 676 | 618 | 650 | 727 | 651 | 636 | 635 | |
| Profit before tax | Rs m | -4,795 | -279 | -160 | -1,160 | -911 | -237 | -1,206 | -480 | |
| Tax | Rs m | -170 | -191 | 265 | 352 | -49 | -10 | -437 | -341 | |
| Profit after tax | Rs m | -4,626 | -88 | -426 | -1,513 | -862 | -228 | -769 | -139 | |
| Gross profit margin | % | -46.9 | 2.1 | 4.6 | -0.4 | 1.3 | 6.7 | -1.7 | 5.7 | |
| Effective tax rate | % | 3.5 | 68.4 | -165.8 | -30.4 | 5.4 | 4.0 | 36.3 | 71.0 | |
| Net profit margin | % | -51.9 | -0.9 | -4.2 | -14.9 | -8.6 | -2.0 | -7.3 | -1.4 | |
| Diluted EPS | Rs | -42.0 | -0.8 | -3.9 | -13.7 | -7.8 | -2.1 | -7.0 | -1.3 | |
| Diluted EPS (TTM) | Rs | -47.4 | -49.8 | -62.6 | -60.5 | -26.2 | -27.5 | -30.6 | -18.1 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Wockhardt 4QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: FDC LTD. DIVIS LABORATORIES ALEMBIC PHARMA INDRAPRASTHA MEDICAL DISHMAN PHARMA
Compare WOCKHARDT With: FDC LTD. DIVIS LABORATORIES ALEMBIC PHARMA INDRAPRASTHA MEDICAL DISHMAN PHARMA
Compare WOCKHARDT With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 491 Points Lower; Metal and Energy Stocks Witness Selling(Closing)
After opening the day marginally lower, share markets in India witnessed negative trading activity throughout the day and ended deep in the red.
Views on news
WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)
May 7, 2019 | Updated on May 7, 2019For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)
Jan 29, 2019 | Updated on Jan 29, 2019For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)
Jun 11, 2019One chart that predicted the NBFC crisis back in 2016.
Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)
Jun 6, 2019Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...
FM Nirmala Sitharaman Inherits an Economy Facing a Number of Headwinds(Sector Info)
Jun 4, 2019The Indian economy is in a major slowdown. Will the new finance minister, Nirmala Sitharaman bring the much-needed reforms?
Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)
Jun 10, 2019The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.
More|
| |
WOCKHARDT SHARE PRICE
Jun 17, 2019 03:33 PM
TRACK WOCKHARDT
- Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON WOCKHARDT
WOCKHARDT 5-YR ANALYSIS
COMPARE WOCKHARDT WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.